ArticleCancer immunology, immunotherapy : CII2010
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity.
Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Immunotherapy in melanoma: advances, pitfalls, and future perspectives.Frontiers in molecular biosciences · 2024Review
- MHC heterogeneity and response of metastases to immunotherapy.Cancer metastasis reviews · 2021Review
- Article
- Cancer immunoediting and resistance to T cell-based immunotherapy.Nature reviews. Clinical oncology · 2019Review
- Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer.BMC research notes · 2019Article
- MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.Frontiers in immunology · 2018Article
- Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.Leukemia · 2016Review
- Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.Cancers · 2015Review
- Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.Oncogene · 2014Article
- LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Novel insights into the molecular mechanisms of HLA class I abnormalities.Cancer immunology, immunotherapy : CII · 2012Review
- Lessons from cancer immunoediting in cutaneous melanoma.Clinical & developmental immunology · 2012Review
- Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.Cancer immunology, immunotherapy : CII · 2011Article
- Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Cancer immunology, immunotherapy : CII · 2011Review
- Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.The Journal of biological chemistry · 2010Article
- Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression.Immunologic research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal models are widely used to study the biological behavior of human tumors in vivo. Murine immunodeficient models are used to test novel human anti-tumor therapies, and humanized mice are employed to study immunotherapeutic protocols. We find that human melanoma cell lines lose HLA class I surface expression after growth in immunodeficient mice and that this phenomenon occurs frequently and is reproducible. This HLA loss is due to a coordinated down-regulation of APM and HLA heavy chain expression at the transcriptional level. It is produced by epigenetic modifications and can be reversed by treatment with histone deacetylase inhibitors or IFN-gamma. These HLA alterations only appear during in vivo growth and not during successive in vitro passages. Interestingly, these new tumor variants with HLA class I loss show higher tumorigenicity per se and may represent a more advanced state of the original tumor. Lack of MHC class I expression on tumor cells represents a frequent escape mechanism from the immune response. Our results indicate that tumor variants with alterations in MHC can also appear in vivo after the immunoescape phase in the absence of anti-tumor immune response. Our findings suggest that any studied parameter, i.e., HLA expression, of malignant cells in xenograft models, has to be evaluated before and after growth in immunodeficient mice, in order to design more appropriate immunotherapy and chemotherapy treatments against tumor cells growing in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.